@article{fdi:010086363,
  title = {{R}isks and benefits of oral {HIV} pre-exposure prophylaxis for people with chronic hepatitis {B}},
  author = {{M}ohareb, {A}. {M}. and {L}armarange, {J}oseph and {K}im, {A}. {Y}. and {C}offie, {P}. {A}. and {K}ouame, {M}. {G}. and {B}oyd, {A}. and {F}reedberg, {K}. {A}. and {H}yle, {E}. {P}.},
  editor = {},
  language = {{ENG}},
  abstract = {{I}ndividuals with chronic hepatitis {B} virus ({HBV}) infection who are at substantial risk of {HIV} acquisition benefit from pre-exposure prophylaxis ({P}r{EP}) with tenofovir-based antiviral therapy. {C}onsidering that tenofovir potently inhibits {HBV}, providing {P}r{EP} to individuals with {HBV} effectively results in treatment of their {HBV} infection. {H}owever, some clinicians might be hesitant to initiate {P}r{EP} in people with chronic {HBV} due to unknown risks of {HBV} reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. {U}nfortunately, these knowledge gaps affect scale up of {P}r{EP} among people with chronic {HBV}. {E}merging data regarding the risks and benefits of antiviral cessation in people with chronic {HBV} suggest that {P}r{EP} can be safely initiated despite the risks of non-adherence or discontinuation. {P}eople with chronic {HBV} who stop {P}r{EP} should be closely monitored for {HBV} reactivation and hepatitis flares after antiviral cessation.},
  keywords = {{MONDE}},
  booktitle = {},
  journal = {{L}ancet {HIV}},
  volume = {9},
  numero = {8},
  pages = {{E}585--{E}594},
  ISSN = {2352-3018},
  year = {2022},
  DOI = {10.1016/s2352-3018(22)00123-0},
  URL = {https://www.documentation.ird.fr/hor/fdi:010086363},
}